Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. Sarepta Therapeutics was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Sarepta Therapeutics news
01.03.2023
Sarepta Therapeutics' GAAP loss for 2022 was $703.49 million, up 68% from $418.78 million in the previous year. Revenue increased 32.9% to $933 million from $701.89 million a year earlier.
Source: 
investorrelations.sarepta.com
investorrelations.sarepta.com
03.11.2022
Sarepta Therapeutics reported a GAAP loss of $594.244 million for 9 months of 2022, doubling from $296.799 million in the previous year. Revenue increased 34.8% to $674.586 million from $500.426 million a year earlier.
Source: investorrelations.sarepta.com
investorrelations.sarepta.com
03.08.2022
Sarepta Therapeutics' GAAP loss for 6 months of 2022 was $336.51 million, up 35.3% from $248.66 million in the prior year. Revenue increased 42.9% to $444.31 million from $311.02 million a year earlier.
Source: investorrelations.sarepta.com
investorrelations.sarepta.com
05.05.2022
Sarepta Therapeutics' GAAP loss for 3 months of 2022 was $105.025 million, down 37.2% from $167.25 million in the previous year. Revenue increased 43.5% to $210.83 million compared to $146.931 million a year earlier.
Source: investorrelations.sarepta.com
investorrelations.sarepta.com
General information
| Company name | Sarepta Therapeutics |
|---|---|
| Tags | #biotechnology, #genome |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000 |
| Mailing address | 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 |
| Website | www.sareptatherapeutics.com |
| Information disclosure | www.sec.gov |
English (US) 